Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients included in ETNA-AF-Europe

From: Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

Characteristic Total Edoxaban 60 mg OD Edoxaban 30 mg OD
Patients, N (%) 13,638 (100) 10,444 (76.6) 3194 (23.4)
Male, % 56.6 60.6 43.5
Age, years, mean (SD) 73.6 (9.52) 71.8 (9.23) 79.6 (7.87)
By age sub-groups, %
  < 65 years 15.4 18.8 4.1
 65–74 years 33.7 38.5 18.0
 75–84 years 40.3 37.3 50.4
  ≥ 85 years 10.6 5.4 27.5
Body weight, kg, mean (SD) 81.0 (17.34) 83.5 (16.77) 72.8 (16.63)
BMI, kg/m2, mean (SD) 28.1 (5.14) 28.6 (5.06) 26.5 (5.07)
SBP, mmHg, mean (SD) 133.4 (18.04) 133.7 (17.90) 132.6 (18.46)
DBP, mmHg, mean (SD) 78.3 (10.90) 79.0 (10.91) 76.2 (10.60)
Current smoking, % 6.3 6.9 4.4
Alcohol, %
 No 44.8 42.0 54.0
CrCl (reported), mL/min, mean (SD) 69.4 (24.23) 75.5 (22.65) 50.8 (18.90)
By CrCl subgroups, %
  < 15 0.6 0.7 0.2
  (15, 30) 1.9 0.3 6.8
  (30, 50) 18.0 6.7 52.9
  (50, 80) 48.2 53.6 31.6
  ≥ 80 31.3 38.7 8.5
Patients with dose reduction criteria, %
 Body weight ≤ 60 kg, % 10.4 5.0 27.6
 CrCl 15–50 mL/min, % 19.9 7.0 59.7
 Concomitant use of P-gp inhibitorsa, % 1.0 0.9 1.5
(calc.) CHADS2, mean (SD) 1.7 (1.07) 1.6 (1.05) 2.1 (1.03)
(calc.) CHA2DS2-VASc, mean (SD) 3.1 (1.40) 2.9 (1.37) 3.8 (1.26)
 CHASDS2-VASc score = 0, % 2.3 2.8 0.3
 CHASDS2-VASc score = 1, % 10.3 12.6 2.5
(calc.) HAS-BLED, mean 2.6 (1.13) 2.4 (1.11) 3.0 (1.10)
Frailtyb, %
 Yes 10.6 6.1 25.3
 No 82.7 87.3 67.4
 Not known 6.7 6.6 7.3
Previous history of CV disease, %
 Hypertension 76.9 75.9 80.0
 Congestive heart failure 5.8 4.7 9.5
 Myocardial infarction 4.3 3.7 6.2
 Angina pectoris 1.5 1.3 2.1
 Valvular disease 17.7 16.2 22.9
 Peripheral artery disease 3.3 2.8 5.2
Previous history of diabetes mellitus, % 21.9 20.5 26.7
Previous history of stroke and ICH, %
 Ischaemic stroke 5.9 5.6 6.9
 Stroke, unknown 0.6 0.5 0.8
 Transient ischaemic attack 3.3 3.2 3.7
 Intracranial haemorrhage 0.5 0.4 0.6
Previous history of bleeding, %
 Any bleeding 3.1 2.5 5.2
 GI bleeding (Major or CRNM) 0.8 0.5 1.7
  Major 1.0 0.8 1.6
  CRNM 1.0 0.8 1.8
  Minor 1.1 0.9 1.8
Renal disease (including dialysis), % 27.0 19.5 51.6
Current AF type, %
 Paroxysmal 53.6 54.5 50.4
 Persistent 24.4 25.3 21.2
 Long-standing persistent 2.4 2.3 2.9
 Permanent 19.6 17.8 25.5
Time since first AF diagnosis, months
 Mean (SD) 25.7 (46.88) 24.9 (47.01) 28.4 (46.37)
 IQ, Q1–Q3 29.3–0.4 26.5–0.4 37.5–0.6
Previous use of AF relevant medication, %
 VKA 16.9 16.3 18.9
 NOAC (other) 8.0 6.9 11.6
 Antiarrrhythmics 5.0 5.0 4.8
 Antiplatelet 15.1 14.8 16.2
  1. a P-gp inhibitors requiring edoxaban dose reduction: cyclosporine, dronedarone, erythromycin, ketoconazole
  2. b There was no specific definition for frailty; it was left to the discretion of the physician to categorise a patient as frail
  3. AF atrial fibrillation, BMI body mass index, CKD chronic kidney disease, CrCl creatinine clearance, CRNM clinically relevant non-major, CV cardiovascular, DBP diastolic blood pressure, GI gastrointestinal, ICH intracranial haemorrhage, IQ interquartile range, NOAC non-vitamin K antagonist oral anticoagulant, NSAIDs non-steroidal anti-inflammatory drugs, OD once daily, P-gp P-glycoprotein, SBP systolic blood pressure, SD standard deviation, VKA vitamin K antagonist